Table 4.
Overview of published PRRT results in pulmonary NET
| Author | Year/Type | Radioligand | n | ORR (%) | DCR (%) | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|
| van Essen | 2007/RS | 177Lu-DOTATATE | 9 | 55 | 89 | 31 | NA |
| Pfeifer | 2011/RS | 90Y-DOTATOC/177Lu-DOTATOC | 6 | 17 | 67 | NA | NA |
| Imhof | 2011/RS | 90Y-DOTATOC | 84 | 29 | NA | NA | 40 |
| Filice | 2012/RS | 90Y-DOTATOC/177Lu-DOTATATE | 13 | 62 | 85 | NA | NA |
| Mariniello | 2016/RS | 90Y-DOTATOC/177Lu-DOTATATE | 114 | 13 | 67 | 28 | 59* |
| Sabet | 2017/RS | 177Lu-DOTATATE | 22 | 27 | 68 | 27 | 42 |
RS, retrospective study; ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival; OS, overall survival; NA, not available;
*
Estimated overall survival. Note the lacking survival data from larger reports on primarily mixed NET cohorts.